Evidence map›Paper›PMID 33554306›Full record

ReviewMolecular diversity2021

In silico design of novel aptamers utilizing a hybrid method of machine learning and genetic algorithm.

Mahsa Torkamanian-Afshar, Sajjad Nematzadeh, Maryam Tabarzad, Ali Najafi, Hossein Lanjanian, Ali Masoudi-Nejad

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular diversity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. A contemporary review on the important role ofInformatics in medicine unlocked · 2022
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mahsa Torkamanian-AfsharDepartment of Bioinformatics, Kish International Campus, University of Tehran, Kish Island, Iran.
Sajjad NematzadehDepartment of Computer Technologies, Beykent University, Istanbul, Turkey.
Maryam TabarzadProtein Technology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Ali NajafiMolecular Biology Research Center, Systems Biology and Poisonings Institute, Tehran, Iran.
Hossein LanjanianCellular and Molecular Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Ali Masoudi-NejadDepartment of Bioinformatics, Kish International Campus, University of Tehran, Kish Island, Iran. amasoudin@ut.ac.ir.ORCID http://orcid.org/0000-0003-0659-5183

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aptamers can be regarded as efficient substitutes for monoclonal antibodies in many diagnostic and therapeutic applications. Due to the tedious and prohibitive nature of SELEX (systematic evolution of ligands by exponential enrichment), the in silico methods have been developed to improve the enrichment processes rate. However, the majority of these methods did not show any effort in designing novel aptamers. Moreover, some target proteins may have not any binding RNA candidates in nature and a reductive mechanism is needed to generate novel aptamer pools among enormous possible combinations of nucleotide acids to be examined in vitro. We have applied a genetic algorithm (GA) with an embedded binding predictor fitness function to in silico design of RNA aptamers. As a case study of this research, all steps were accomplished to generate an aptamer pool against aminopeptidase N (CD13) biomarker. First, the model was developed based on sequential and structural features of known RNA-protein complexes. Then, utilizing RNA sequences involved in complexes with positive prediction results, as the first-generation, novel aptamers were designed and top-ranked sequences were selected. A 76-mer aptamer was identified with the highest fitness value with a 3 to 6 time higher score than parent oligonucleotides. The reliability of obtained sequences was confirmed utilizing docking and molecular dynamic simulation. The proposed method provides an important simplified contribution to the oligonucleotide-aptamer design process. Also, it can be an underlying ground to design novel aptamers against a wide range of biomarkers.

Indexed as

AlgorithmsMachine LearningMolecular Docking SimulationMolecular Dynamics SimulationAptamers, NucleotideBiomarkersCD13 AntigensDrug DesignLigandsMolecular ConformationProteinsRNAAptamers, NucleotideBiomarkersCD13 AntigensLigandsProteinsRNAAminopeptidase N (CD13)AptamerDockingGenetic algorithm (GA)Molecular dynamic simulation

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.